Nordisk's - QuikReader

Ozempic maker Novo Nordisk nudges higher profit forecast

Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.

Business - MarketWatch - 6 days ago

Novo Nordisk shares jump 8% after Wegovy sales beat expectations

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance.

Business - CNBC - 6 days ago

Novo Nordisk's Wegovy Sales Beat Expectations

The pharmaceutical giant’s blockbuster weight-loss drug beat sales expectations in the third quarter, sending shares higher in early trade.

Business - The Wall Street Journal - 6 days ago

The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide — while adding great heft to the economy of Novo Nordisk’s home country, Denmark.

With Novo Nordisk success, is there a "Nokia risk" for Denmark?

Correspondent Jon Wertheim revisits 60 Minutes' coverage of former mobile giant Nokia and discusses potential risks for the Danish economy.

Novo Nordisk's obesity-fighting drugs fatten Denmark's economy

Danish company Novo Nordisk has a market cap larger than the entire country's GDP. As it grows, it's having an impact on other industries.

Weight loss drug industry injects wealth into Novo Nordisk home country

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great heft to the economy of Novo Nordisk's home country, Denmark.

Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says

It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.

Business - CNBC - October 30

Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in diabetes patients.

Business - CNBC - October 24

Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes ...

Politics - The Hill - October 23

Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for those manufacturers to make safely.

Business - CNBC - October 23

Novo Nordisk New Pill Reduces Heart Attacks, Strokes in Diabetic Patients

The Wegovy maker’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14%, according to a new trial.

Business - The Wall Street Journal - October 21

Latest in Nordisk's